Operating Models for R&D Excellence –
February 2008; Vol. 3 No. 1

How drug developers organize their companies affects operational and financial performance: The results of the study concluded that in order to speed the pace of new drug development, pharmaceutical and biopharmaceutical companies will not only partner with each other, but will also form strong alliances with organizations outside the drug development industry.

“Even though small-mid tier pharma and biotech are helping to fill the product development gap, new, more complex products raise the costs of late stage clinical failures for all develop.”